{"nctId":"NCT03875729","briefTitle":"Recent-Onset Type 1 Diabetes Trial Evaluating Efficacy and Safety of Teplizumab","startDateStruct":{"date":"2019-04-05","type":"ACTUAL"},"conditions":["Type 1 Diabetes Mellitus"],"count":328,"armGroups":[{"label":"Teplizumab","type":"EXPERIMENTAL","interventionNames":["Biological: teplizumab"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Biological: Placebo"]}],"interventions":[{"name":"teplizumab","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Is 8 to 17 years of age, inclusive, at the time of randomization/initiation of study drug administration.\n2. Has received a diagnosis of type 1 diabetes (T1D) according to the criteria from the American Diabetes Association.\n3. Is able to be randomized and initiate study drug within 6 weeks (42 days) of the formal T1D diagnosis.\n4. Has a peak stimulated C-peptide of â‰¥0.2 pmol/mL from a mixed meal tolerance test (MMTT) at screening.\n5. Has a positive result on testing for T1D-related autoantibodies.\n\nExclusion Criteria:\n\n1. Has any autoimmune disease other than T1D with the exception of stable thyroid or celiac disease.\n2. Has an active infection and/or fever.\n3. Has a history of or serologic evidence at screening of current or past infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV).\n4. An individual who has a medical, psychological or social condition that, in the opinion of the Principal Investigator, would interfere with safe and proper completion of the trial.","healthyVolunteers":false,"sex":"ALL","minimumAge":"8 Years","maximumAge":"17 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in C-peptide ln(AUC+1) Standardized by Duration of the Mixed Meal Tolerance Test (MMTT)","description":"The area under the concentration-time curve (AUC) of C-peptide was measured after a 4-hour mixed meal tolerance test (MMTT) and is a measure of endogenous insulin production and Î² cell function. The AUC was computed using the trapezoidal rule and standardized by the duration of the MMTT test, i.e., AUC was divided by the last blood sample collection time (240 minutes or the last collection time for 4h MMTT).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2112","spread":null},{"groupId":"OG001","value":"-0.0859","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2185","spread":null},{"groupId":"OG001","value":"-0.0800","spread":null}]}]}]},{"type":"SECONDARY","title":"Average Daily Exogenous Insulin Use","description":"The average daily insulin use was calculated based on participants who have at least 3 days of insulin use recorded in the dairy for the Week 78 visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.593","spread":null},{"groupId":"OG001","value":"0.463","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.613","spread":null},{"groupId":"OG001","value":"0.446","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Glycated Hemoglobin (HbA1c) Levels (%)","description":"Change in percentage (%) glycated hemoglobin (HbA1c)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.89","spread":null},{"groupId":"OG001","value":"-1.98","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.94","spread":null},{"groupId":"OG001","value":"-2.07","spread":null}]}]}]},{"type":"SECONDARY","title":"Time in Range for Glycemia Control","description":"Time in range (%) for glycemia control was assessed using Continuous Glucose Monitoring (CGM). Time in range was defined as daily average percentage of time a participant's glucose is \\>= 70 mg/dL and \\<=180 mg/dL. Time in range was calculated based on participants who had at least 3 days of CGM data recorded for Week 78 visit with a range of at least 8 hours on a given day.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"62.65","spread":null},{"groupId":"OG001","value":"67.36","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61.44","spread":null},{"groupId":"OG001","value":"67.61","spread":null}]}]}]},{"type":"SECONDARY","title":"Rate of Clinically Important Hypoglycemic Events","description":"Rate = clinically important hypoglycemic events/patient-year. A clinically important episode was defined as a blood glucose value of \\<54 mg/dL (3.0 mmol/L) (i.e., Level 2 Hypoglycemia, International Hypoglycemia Study Group, 2017) or a hypoglycemia event of severe cognitive impairment requiring external assistance (such as seizure, syncope, severe confusion with or without a confirmatory low blood glucose reading) (i.e., Level 3 Hypoglycemia, International Hypoglycemia Study Group 2017). Event rate was calculated for each participant as number of events / total study follow-up time. Total study follow-up time was calculated as (the date of last study contact - the first dose date + 1)/365.25. The summary is based on the data reported post-baseline in the Hypoglycemic Events Electronic Diary (eDiary).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.24","spread":null},{"groupId":"OG001","value":"4.68","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.63","spread":null},{"groupId":"OG001","value":"5.04","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Adverse Events of Special Interest (AESIs)","description":"AESIs are defined in the protocol and categories in the statistical analysis plan. Participants with multiple events are counted only once for each preferred term and category.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null},{"groupId":"OG001","value":"63","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"29","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Teplizumab Serum Concentrations","description":"PK samples were collected prior to dosing except for Day 9 in Course 1. An additional PK sample was collected 45 minutes after infusion on Day 9 in Course 1. Concentration values below Lower Limit of Quantification (2.50 ng/mL) were set to zero for summary statistics. Course 2 day numbers were set relative to the first day of dosing, regardless of normal or modified dosing schedule.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.4271","spread":"628.114"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70.4769","spread":"50.767"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"250.3928","spread":"44.677"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"636.4390","spread":"33.171"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"305.6569","spread":"47.048"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25.0317","spread":"79.953"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.5433","spread":"522.457"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"82.0166","spread":"50.333"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"145.9498","spread":"75.737"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"108.2988","spread":"107.776"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.2159","spread":"181.421"}]}]}]},{"type":"SECONDARY","title":"Anti-teplizumab Antibody (ADA) Titers After Treatment Courses","description":"Baseline was defined as the most recent value collected prior to the first dose of study drug. Week 26 Day 187 and Weeks 27 and 34 are planned for subjects under the normal dosing schedule. Week 52 Day 369 and Weeks 53, 56, and 60 are planned for subjects under the modified dosing schedule.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"65.81","spread":"182.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"177.22","spread":"278.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"817.08","spread":"275.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1040.58","spread":"239.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"834.86","spread":"226.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"807.26","spread":"681.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9257.15","spread":"222.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9985.29","spread":"218.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7326.91","spread":"237.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3701.64","spread":"202.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1398.22","spread":"240.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"308.80","spread":"207.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8043.22","spread":"165.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14221.44","spread":"241.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9040.49","spread":"299.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"996.15","spread":"484.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"672.13","spread":"332.4"}]}]}]},{"type":"SECONDARY","title":"Incidence of Anti-drug Antibodies (ADA) After Treatment Courses","description":"Baseline is defined as the most recent value collected prior to the first dose of study drug. Week 26 Day 187 and Weeks 27 and 34 are planned for subjects under the normal dosing schedule. Week 52 Day 369 and Weeks 53, 56, and 60 are planned for subjects under the modified dosing schedule.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null}]},{"measurements":[{"groupId":"OG000","value":"200","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"182","spread":null}]},{"measurements":[{"groupId":"OG000","value":"25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"178","spread":null}]},{"measurements":[{"groupId":"OG000","value":"26","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"175","spread":null}]},{"measurements":[{"groupId":"OG000","value":"31","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"139","spread":null}]},{"measurements":[{"groupId":"OG000","value":"53","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"130","spread":null}]},{"measurements":[{"groupId":"OG000","value":"40","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"167","spread":null}]},{"measurements":[{"groupId":"OG000","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"169","spread":null}]},{"measurements":[{"groupId":"OG000","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"163","spread":null}]},{"measurements":[{"groupId":"OG000","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"170","spread":null}]},{"measurements":[{"groupId":"OG000","value":"22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"155","spread":null}]},{"measurements":[{"groupId":"OG000","value":"37","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null}]},{"measurements":[{"groupId":"OG000","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null}]},{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null}]},{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null}]},{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"153","spread":null}]},{"measurements":[{"groupId":"OG000","value":"38","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"146","spread":null}]},{"measurements":[{"groupId":"OG000","value":"45","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":6,"n":111},"commonTop":["Hypoglycaemia","Headache","Nausea","Rash","Vomiting"]}}}